Retraction to: Xenotransplantation of human adipose derived mesenchymal stem cells in a rodent model of Huntington’s disease: motor and non-motor outcomes (Neurological Research, (2015), 37, 4, (309-319), 10.1179/1743132814Y.0000000456);Xenotransplantation of human adipose derived mesenchymal stem cells in a rodent model of Huntington’s disease: Motor and non-motor outcomes

Neurological Research

Volumn 37, Issue 4, 2015, Pages 309-319

  Hosseini, Mahmoud ^a   Moghadas, Marzieh ^b   Edalatmanesh, Mohammad Amin ^b   Hashemzadeh, Mohammad Reza ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c Eram Centre   (Iran)

Author keywords

Adipose derived mesenchymal stem cells; Anxiety; Huntington s disease; Locomotor activity

Indexed keywords

ENDOGLIN; HERMES ANTIGEN; QUINOLINIC ACID; THY 1 ANTIGEN;

ADIPOSE DERIVED STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; APOMORPHINE INDUCED ROTATION TEST; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION ASSAY; CELL ISOLATION; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HANGING WIRE TEST; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; LENTIVIRINAE; LIGHT AND DARK BOX TEST; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD TEST; RAT; ROTATING ROD TEST; XENOTRANSPLANTATION; ADIPOSE TISSUE; ANIMAL; CORPUS STRIATUM; CYTOLOGY; DISEASE MODEL; HUNTINGTON DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROCEDURES; PSYCHOLOGY; ROTAROD TEST; WISTAR RAT; XENOGRAFT;

ADIPOSE TISSUE; ANIMALS; ANXIETY; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MOTOR ACTIVITY; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; TRANSPLANTATION, HETEROLOGOUS;

EID: 84921725668     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1080/01616412.2017.1298496     Document Type: Erratum

References (53)

1. Picconi B, Passino E, Sgobio C, Bonsi P, Barone I, Ghiglieri V, et al. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis. 2006;22:143-52.
2. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench- Constant C, Rubinsztein DC, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998;121(Pt 7):1329-41.
3. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, et al. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci. 2000;20:5115-23.
4. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986;321:168- 71.
5. Freeman TB, Hauser RA, Sanberg PR, Saporta S. Neural transplantation for the treatment of Huntington's disease. Prog. Brain Res. 2000;127:405-11.
6. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem. 2006;96(4):1121-9.
7. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci. 1991;11:1649-59.
8. Sanberg PR, Koutouzis TK, Freeman TB, Cahill DW, Norman AB. Behavioral effects of fetal neural transplants: relevance to Huntington's disease. Brain Res Bull. 1993;32:493-6.
9. Furtado JC, Mazurek MF. Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease. Exp Neurol. 1996;138(1):158-68.
10. Haik KL, Shear DA, Schroeder U, Sabel BA, Dunbar GL. Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease. Exp Neurol. 2000;163(2):430-9.
11. Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pèzzola A, et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acidinduced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci. 2002;22(5):1967-75.
12. Edalatmanehs MA, Matin MM, Neshati Z, Bahrami AR. Systemic transplantation of mesenchymal stem cells can reduce cognitive and motor deficits in rats with unilateral lesions of the neostriatum. Neurol Res. 2010;32(2):166-72.
13. Armstrong RJ, Svendsen CN. Neural stem cells: from cell biology to cell replacement. Cell Transplant. 2000;9:139-52.
14. Dunnett SB, Kendall AL, Watts C, Torres EM. Neuronal cell transplantation for Parkinson's and Huntington's diseases. Br Med Bull. 1997;53:757-76.
15. Peschanski M, Cesaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience. 1995;68:273-85.
16. Svendsen CN, Caldwell MA. Neural stem cells in the developing central nervous system: implications for cell therapy through transplantation. Prog Brain Res. 2000;127:13-34.
17. McKay R. Stem cells in the central nervous system. Science. 1997;276(5309):66-71.
18. Flax JD, Aurora S, Yang C, Simonin C, Wills AM, Billinghurst LL, et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol. 1998;16(11):1033-9.
19. Madonna R, Geng YJ, De Caterina R. Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. Arterioscler Thromb Vasc Biol. 2009;29(11):1723-9.
20. Vieira NM, Brandalise V, Zucconi E, Jazedje T, Secco M, Nunes VA, et al. Human multipotent adipose-derived stem cells restore dystrophin expression of Duchenne skeletal-muscle cells in vitro. Biol Cell. 2008;100(4):231-41.
21. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13(12):4279-95.
22. Rodriguez AM, Elabd C, Amri EZ, Ailhaud G, Dani C. The human adipose tissue is a source of multipotent stem cells. Biochimie. 2005;87(1):125-8.
23. Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE, et al. Multipotential differentiation of adipose tissuederived stem cells. Keio J Med. 2005;54(3):132-41.
24. Sowa Y, Imura T, Numajiri T, Nishino K, Fushiki S. Adiposederived stem cells produce factors enhancing peripheral nerve regeneration: influence of age and anatomic site of origin. Stem Cells Dev. 2012;21(11):1852-62.
25. Taha MF, Hedayati V. Isolation, identification and multipotential differentiation of mouse adipose tissue-derived stem cells. Tissue Cell. 2010;42(4):211-6.
26. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med. 2008;14(5):507-9.
27. Nakao N, Nakayama T, Yahata T, Muguruma Y, Saito S, Miyata Y, et al. Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Am J Pathol. 2010;177(2):547-54.
28. Ahmadian Kia N, Bahrami AR, Ebrahimi M, Matin MM, Neshati Z, Almohaddesin MR, et al. Comparative analysis of chemokine receptor's expression in mesenchymal stem cells derived from human bone marrow and adipose tissue. J Mol Neurosci. 2011;44(3):178-85.
29. Zufferey R, Dull T, Mandel Rj, Bukovsky A, Quiroz D, Naldini L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873-80.
30. Haddad-Mashadrizeh A, Bahrami AR, Matin MM, Edalatmanesh MA, Zomorodipour A, Fallah A, et al. Evidence for crossing the blood barrier of adult rat brain by human adipose-derived mesenchymal stromal cells during a 6-month period of post-transplantation. Cytotherapy. 2013;15(8):951- 60.
31. Edalatmanesh MA, Bahrami AR, Hosseini E, Hosseini M, Khatamsaz S. Bone marrow derived mesenchymal stem cell transplantation in cerebellar degeneration: a behavioral study. Behav Brain Res. 2011;225(1):63-70.
32. Scattoni ML, Valanzano A, Popoli P, Pezzola A, Reggio R, Calamandrei G. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease. Behav Brain Res. 2004;152:375-83.
33. Scattoni ML, Valanzano A, Pezzola A, March ZD, Fusco FR, Popoli P, et al. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. Behav Brain Res. 2007;176(2):216-21.
34. Novais A, Ferreira AC, Marques F, Pêgo JM, Cerqueira JJ, David-Pereira A, et al. Neudesin is involved in anxiety behavior: structural and neurochemical correlates. Front Behav Neurosci. 2013;7:119.
35. Amin EM, Reza BA, Morteza BR, Maryam MM, Ali M, Zeinab N. Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration. Neurol Res. 2008;30(10):1086-90.
36. Edalatmanesh MA, Bahrami AR, Hosseini E, Hosseini M, Khatamsaz S. Neuroprotective effects of mesenchymal stem cell transplantation in animal model of cerebellar degeneration. Neurol Res. 2011;33(9):913-20.
37. Roberts JT, Price SJ, Williams RC, Modo M. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease. Neuroscience. 2006;139:1187-99.
38. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: How can we make it work? Trends Neurosci. 2005;28:86-92.
39. Lin YT, Chern Y, Shen CK, Wen HL, Chang YC, Li H, et al. Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS One. 2011;6(8):e22924.
40. Levi B, James AW, Nelson ER, Vistnes D, Wu B, Lee M, et al. Human adipose derived stromal cells heal critical size mouse calvarial defects. PLoS One. 2010;5(6):e11177.
41. Gimble JM, Nuttall ME. Adipose-derived stromal/stem cells (ASC) in regenerative medicine: pharmaceutical applications. Curr Pharm Des. 2011;17(4):332-9.
42. De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, et al. Differential expression of stem cell mobilization- associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett. 2003;89(2-3):267-70.
43. Han ZB, Chen HX, Deng JX. Multipotential differentiation and potential applications of adipose-derived stem cells. Sheng Wu Gong Cheng Xue Bao. 2007;23(2):195-200.
44. Shen LH, Li Y, Chen J, Zhang J, Vanguri P, Borneman J, et al. Intracarotid transplantation of bone marrow stromal cells increases axon-myelin remodeling after stroke. Neuroscience. 2006;137:393-9.
45. Shyu WC, Lin SZ, Chiang MF, Su CY, Li H. Intracerebral peripheral blood stem cell (CD34z) implantation induces neuroplasticity by enhancing beta1 integrin-mediated angiogenesis in chronic stroke rats. J Neurosci. 2006;26:3444-53.
46. Schackel S, Pauly MC, Piroth T, Nikkhah G, Döbrössy MD. Donor age dependent graft development and recovery in a rat model of Huntington's disease: histological and behavioral analysis. Behav Brain Res. 2013;256:56-63.
47. Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, et al. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease. Exp Neurol. 2012;234(2):417-27.
48. Grillner S, Hellgren J, Menard A, Saitoh K, Wikstrom M. Mechanisms for selection of basic motor programs-roles for the striatum and pallidum. Trends Neurosci. 2005;28:364-70.
49. Dunnett SB, Nathwani F, Brasted PJ. Medial prefrontal and neostriatal lesions disrupt performance in an operant delayed alternation task in rats. Behav Brain Res. 1999;106:13-28.
50. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71:310-4.
51. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS. 2011;8(1):4.
52. Prigozhina Tb, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol. 2008;36(10):1370-6.
53. Lin Y, Hogan Wj. Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv Hematol. 2011; 427863.